Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fevipiprant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 known ✓ | Q9Y5Y4 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fevipiprant SCHEMBL1940595 | 1.00 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL1939556 | 0.92 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL21591931 | 0.90 | PTGDR2 (0.82) | PTGDR2 | |
| SCHEMBL1940778 | 0.90 | PTGDR2 (0.82) | PTGDR2 | |
| SCHEMBL20508235 | 0.90 | PTGDR2 (0.81) | PTGDR2 | |
| SCHEMBL21913709 | 0.89 | PTGDR2 (0.80) | PTGDR2 | |
| SCHEMBL1940435 | 0.88 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL1941189 | 0.87 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL1941253 | 0.87 | PTGDR2 (0.82) | PTGDR2 | |
| SCHEMBL28356397 | 0.87 | PTGDR2 (0.76) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 224 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12533095-B1 | Airway mucus scoring system | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-01-27 | — | — | US | claimed |
| WO-2025264860-A2 | METHODS OF TREATING POST-COVID AIRWAY DISEASE | YALE UNIVERSITY (US) | 2025-12-26 | — | — | WO | claimed |
| US-20250381192-A1 | Treatment of Autoimmune Disease | JAK SLAVE PTY LTD (AU) | 2025-12-18 | — | — | US | claimed |
| US-12364696-B2 | Treatment of autoimmune disease | JAK SLAVE PTY LTD (AU) | 2025-07-22 | — | — | US | claimed |
| WO-2024192765-A1 | FIRST IN CLASS USE OF THE CRTH2 ANTAGONIST IN TREATING NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) AND RELEVANT AUTOIMMUNE CNS DISORDERS | BROWN UNIVERSITY (US) | 2024-09-26 | — | — | WO | claimed |
| US-12091708-B2 | Compositions and methods targeting the Th2 pathway for the treatment of asthma | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2024-09-17 | — | — | US | claimed |
| US-20240226057-A1 | NEW USE OF MONENSIN | MAST PHARMA AB (SE) | 2024-07-11 | — | — | US | claimed |
| EP-4378957-A2 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO PD-1 | Novartis AG (CH) | 2024-06-05 | — | — | EP | claimed |
| US-20240148745-A1 | COMPOUNDS FOR USE IN PROGRESSIVE MULTIPLE SCLEROSIS | FONDAZIONE CENTRO SAN RAFFAELE (IT) | 2024-05-09 | — | — | US | claimed |
| EP-4362934-A1 | NEW USE OF MONENSIN | Mast Pharma AB (SE) | 2024-05-08 | — | — | EP | claimed |
| CN-117612741-A | Novel coronavirus infection metabolic profile, and construction method, device, system and application thereof | 首都医科大学附属北京朝阳医院 | 2024-02-27 | — | — | CN | claimed |
| EP-4304719-A1 | COMPOUNDS FOR USE IN PROGRESSIVE MULTIPLE SCLEROSIS | Fondazione Centro San Raffaele (IT) | 2024-01-17 | — | — | EP | claimed |
| WO-2023277761-A1 | NEW USE OF MONENSIN | PEJLER GUNNAR (SE) | 2023-01-05 | — | — | WO | claimed |
| WO-2022189531-A1 | COMPOUNDS FOR USE IN PROGRESSIVE MULTIPLE SCLEROSIS | FONDAZIONE CENTRO SAN RAFFAELE (IT) | 2022-09-15 | — | — | WO | claimed |
| EP-4056231-A1 | COMPOUNDS FOR USE IN PROGRESSIVE MULTIPLE SCLEROSIS | Fondazione Centro San Raffaele (IT) | 2022-09-14 | — | — | EP | claimed |
| US-20220259656-A1 | BLOOD BIOMARKER AND GENETIC MARKERS ASSOCIATED WITH RESPONSE TO CRTH2 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-08-18 | — | — | US | claimed |
| EP-3337803-B1 | GENETIC MARKERS ASSOCIATED WITH RESPONSE TO CRTH2 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC (US) | 2022-08-17 | — | — | EP | claimed |
| US-20220187316-A1 | Postural Orthostatic Tachycardia Syndrome and CRTH2 | AMERIMMUNE DIAGNOSTICS LLC | 2022-06-16 | — | — | US | claimed |
| US-20220143025-A1 | TREATMENT OF AUTOIMMUNE DISEASE | JAK SLAVE PTY LTD (AU) | 2022-05-12 | — | — | US | claimed |
| EP-3941579-A1 | POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME AND CRTH2 | Amerimmune, LLC (US) | 2022-01-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12364696-B2 | Treatment of autoimmune disease | JAK1, JAK3, JAK2 | PTGDR2 2062/4885 |
| US-20250381192-A1 | Treatment of Autoimmune Disease | JAK1, JAK3, JAK2 | PTGDR2 2062/4885 |
| US-20220143025-A1 | TREATMENT OF AUTOIMMUNE DISEASE | JAK1, JAK3, JAK2 | PTGDR2 2062/4885 |
| US-20240226057-A1 | NEW USE OF MONENSIN | MRGPRX1, MRGPRX2, CMA1 | PTGDR2 1558/4885 |
| US-12533095-B1 | Airway mucus scoring system | MUC1, IL5, CYSLTR2 | PTGDR2 637/4885 |
| US-20220259656-A1 | BLOOD BIOMARKER AND GENETIC MARKERS ASSOCIATED WITH RESPONSE TO CRTH2 RECEPTOR ANTAGONISTS | HRH2, HRH1, CRHR2 | PTGDR2 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.